SCHEDULE: Lytton and Foundation Adjust Aytu BioPharma Stake

Laurence W. Lytton and the Lytton-Kambara Foundation have jointly filed an update regarding their beneficial ownership of Aytu BioPharma, Inc. common stock, maintaining their holdings below the 5% threshold.

Summary

• This filing is an amendment to a Schedule 13G, reporting changes in beneficial ownership of Aytu BioPharma, Inc. common stock.
• Laurence W. Lytton and the Lytton-Kambara Foundation are jointly filing this statement.
• The total beneficial ownership for both Laurence W. Lytton and the Lytton-Kambara Foundation is reported as 545,946 shares each.
• This represents 4.99% of the class of securities for each reporting person.
• The percentages are based on 10,733,208 shares of Common Stock outstanding as of March 31, 2026.
• The filing confirms that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership thresholds rather than a significant operational or financial event.

Positives

• The reporting persons have maintained their beneficial ownership below the 5% threshold, indicating no intent to gain controlling interest.
• The joint filing agreement ensures coordinated reporting for these entities.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Aytu BioPharma, Inc.

Risks

• The beneficial ownership is subject to a 4.99% limitation, which could necessitate adjustments if the number of outstanding shares changes significantly.
• The filing does not detail the specific nature of the warrants held, which could represent future dilution or voting power.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely addresses beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine for institutional investors and significant individual holders to report ownership stakes. This filing indicates that Laurence W. Lytton and the Lytton-Kambara Foundation are maintaining their positions as passive investors below the threshold that would trigger more stringent reporting requirements.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership stakes, reassuring investors that current holders are not seeking control changes.
• Management: Confirms that key stakeholders are adhering to reporting requirements.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G as required by SEC regulations for any material changes in beneficial ownership.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Aytu BioPharma, Laurence W. Lytton, Lytton-Kambara Foundation, common stock, warrants, SEC filing